← ANALYST RATINGS · TIPRANKS
BioMarin Pharmaceutical (BMRN): analyst forecast and price target
Analyst consensus
Strong Buy14 Buy4 Hold0 Sell
Ratings of 18 analysts in the last 3 months · top analysts only12-month forecast
Based on 18 price targets given in the last 3 months, the average target is $93.31, the highest $124, the lowest $60.00. The average is +70.7% from the last price of $54.68.
Analyst ratings 29
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Whitney Ijem★★★★★★★★★★#537 · hits 48% · avg +20.2% | Canaccord Genuity | $114 | Buy | +108.5% | Reiterated | 16.10.26on TipRanks 10:25 | −1.3% | ↗ |
| Joon Lee★★★★★★★★★★#73 · hits 58% · avg +36.3% | Truist Financial | $114 → $88.00−22.8% | Buy | +60.9% | Assigned | 14.10.26on TipRanks Oct 15 06:55 | +2.5%next day +1.4% | ↗ |
| Eliana Merle★★★★★★★★★★#4163 · hits 45% · avg +3.0% | Barclays | $111 → $114+2.7% | Buy | +108.5% | Reiterated | 13.10.26on TipRanks Oct 14 05:00 | −1.8%next day +2.5% | ↗ |
| Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% | Bank of America Securities | $86.00 | Buy | +57.3% | Reiterated | 09.10.26on TipRanks 09:10 | −0.8%next day +1.1% · 5 days +1.8% | ↗ |
| Luca Issi★★★★★★★★★★#11187 · hits 39% · avg −2.1% | RBC Capital | $62.00 | Hold | +13.4% | Reiterated | 08.10.26on TipRanks 21:45 | −0.8%next day +1.1% · 5 days +1.8% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $65.00 → $61.00−6.2% | Buy | +11.6% | Upgrade | 08.10.26on TipRanks 14:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $62.00 → $58.00−6.5% | Hold | +6.1% | Reiterated | 08.10.26on TipRanks 14:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $63.00 → $58.00−7.9% | Hold | +6.1% | Reiterated | 08.10.26on TipRanks 14:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $62.00 → $57.00−8.1% | Hold | +4.2% | Reiterated | 08.10.26on TipRanks 14:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $63.00 → $59.00−6.3% | Hold | +7.9% | Reiterated | 08.10.26on TipRanks 14:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $62.00 → $57.00−8.1% | Hold | +4.2% | Reiterated | 08.10.26on TipRanks 14:05 | — | |
| David Lebowitz★★★★★★★★★★#597 · hits 60% · avg +14.2% | Citi | $97.00 | Buy | +77.4% | Reiterated | 06.10.26on TipRanks Oct 7 09:15 | −2.8%next day −1.6% · 5 days −3.1% | ↗ |
| Jessica Fye★★★★★★★★★★#1182 · hits 56% · avg +9.4% | J.P. Morgan | $86.00 | Buy | +57.3% | Reiterated | 21.09.26on TipRanks 08:09 | −1.4%next day −1.1% · 5 days −6.2% | ↗ |
| Debjit Chattopadhyay★★★★★★★★★★#506 · hits 48% · avg +17.0% | Guggenheim | $86.00 | Buy | +57.3% | Reiterated | 17.09.26on TipRanks Sep 18 07:10 | −0.6%next day −1.9% · 5 days −6.6% | ↗ |
| Sean Laaman★★★★★★★★★★#446 · hits 67% · avg +17.2% | Morgan Stanley | $124 | Buy | +126.8% | Assigned | 16.09.26on TipRanks 08:30 | +0.9%next day −0.6% · 5 days −6.0% | ↗ |
| Eric Joseph★★★★★★★★★★#1258 · hits 52% · avg +11.4% | Citi | — | Buy | — | Reiterated | 14.09.26on TipRanks 13:20 | +1.6%next day −2.5% · 5 days −5.4% | ↗ |
| Mohit Bansal★★★★★★★★★★#754 · hits 60% · avg +10.9% | Wells Fargo | $80.00 | Buy | +46.3% | Reiterated | 11.09.26on TipRanks 06:55 | −0.6%next day +1.6% · 5 days −2.6% | ↗ |
| Mitchell Kapoor★★★★★★★★★★#1086 · hits 45% · avg +12.2% | H.C. Wainwright | $60.00 | Hold | +9.7% | Reiterated | 10.09.26on TipRanks 07:25 | +2.3%next day −0.6% · 5 days −1.3% | ↗ |
| Olivia Brayer★★★★★★★★★★#9632 · hits 39% · avg −1.2% | Cantor Fitzgerald | $85.00 → $86.00+1.2% | Buy | +57.3% | Reiterated | 01.09.26on TipRanks 08:50 | +0.1%next day +2.8% · 5 days −0.7% | ↗ |
| Allison Bratzel★★★★★★★★★★#171 · hits 64% · avg +41.9% | Piper Sandler | $88.00 → $90.00+2.3% | Buy | +64.6% | Reiterated | 01.09.26on TipRanks 07:10 | +0.1%next day +2.8% · 5 days −0.7% | ↗ |
| Salveen Richter★★★★★★★★★★#967 · hits 51% · avg +12.5% | Goldman Sachs | $70.00 | Hold | +28.0% | Reiterated | 31.08.26on TipRanks Sep 1 09:05 | +1.2%next day +0.1% · 5 days −0.8% | ↗ |
| Whitney Ijem★★★★★★★★★★#537 · hits 48% · avg +20.2% | Canaccord Genuity | $114 | Buy | +108.5% | Reiterated | 31.08.26on TipRanks Sep 1 08:35 | +1.2%next day +0.1% · 5 days −0.8% | ↗ |
| Akash Tewari★★★★★★★★★★#649 · hits 57% · avg +13.5% | Jefferies | $104 → $105+1.0% | Buy | +92.0% | Reiterated | 31.08.26on TipRanks 11:15 | +1.2%next day +0.1% · 5 days −0.8% | ↗ |
| Sami Corwin★★★★★★★★★★#511 · hits 55% · avg +18.5% | William Blair | — | Hold | — | Reiterated | 31.08.26on TipRanks 10:55 | +1.2%next day +0.1% · 5 days −0.8% | ↗ |
| Paul Matteis★★★★★★★★★★#473 · hits 53% · avg +17.6% | Stifel Nicolaus | $70.00 | Hold | +28.0% | Reiterated | 31.08.26on TipRanks 07:30 | +1.2%next day +0.1% · 5 days −0.8% | ↗ |
| Phil Nadeau★★★★★★★★★★#1350 · hits 48% · avg +8.7% | TD Cowen | $120 | Buy | +119.5% | Reiterated | 20.08.26on TipRanks Aug 18 12:30 | +1.2%next day +3.3% · 5 days −1.1% | ↗ |
| Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% | Bank of America Securities | $86.00 | Buy | +57.3% | Reiterated | 18.08.26on TipRanks Aug 19 04:45 | +1.2%next day +3.3% · 5 days −1.1% | ↗ |
| Yun Zhong★★★★★★★★★★#12228 · hits 38% · avg −9.6% | Wedbush | $94.00 | Buy | +71.9% | Reiterated | 18.08.26on TipRanks 10:45 | +1.2%next day +3.3% · 5 days −1.1% | ↗ |
| Eliana Merle★★★★★★★★★★#4163 · hits 45% · avg +3.0% | Barclays | $105 → $111+5.7% | Buy | +103.0% | Reiterated | 17.08.26on TipRanks 04:55 | −0.6%next day +1.2% · 5 days −1.2% | ↗ |
| Christopher Raymond★★★★★★★★★★#4074 · hits 45% · avg +2.6% | Raymond James | $100 → $105+5.0% | Buy | +92.0% | Reiterated | 07.08.26on TipRanks 09:40 | +3.2%next day +8.0% · 5 days +5.2% | ↗ |
| Cory Kasimov★★★★★★★★★★#276 · hits 59% · avg +18.9% | Evercore ISI | $120 | Buy | +119.5% | Reiterated | 07.08.26on TipRanks 08:45 | +3.2%next day +8.0% · 5 days +5.2% | ↗ |
| Leland Gershell★★★★★★★★★★#2332 · hits 40% · avg +6.2% | Oppenheimer | $95.00 → $97.00+2.1% | Buy | +77.4% | Assigned | 07.08.26on TipRanks 08:15 | +3.2%next day +8.0% · 5 days +5.2% | ↗ |
| Joseph Schwartz★★★★★★★★★★#135 · hits 54% · avg +31.9% | Leerink Partners | $62.00 | Hold | +13.4% | Reiterated | 18.05.26on TipRanks 14:55 | −4.1%next day +0.9% · 5 days +4.8% | ↗ |
| William Pickering★★★★★★★★★★#5908 · hits 58% · avg +1.8% | Bernstein | $94.00 → $82.00−12.8% | Buy | +50.0% | Assigned | 05.05.26on TipRanks 06:50 | −4.8%next day +1.2% · 5 days −2.7% | ↗ |
| Joon Lee★★★★★★★★★★#73 · hits 58% · avg +36.3% | Truist Financial | — | Buy | — | Reiterated | 03.03.26on TipRanks 08:15 | −1.1%next day +2.5% · 5 days +4.5% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering BioMarin Pharmaceutical
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 08.10.26: target $93.15 at a price of $55.20 (+68.8%); now: $93.05 at $54.68 (+70.2%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 16 | 16 | 15 | 11 | 13 | 16 |
| Buy | 9 | 5 | 6 | 8 | 14 | 13 |
| Hold | 8 | 8 | 11 | 12 | 13 | 10 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 03.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $1.35 (from $1.25 to $1.48). Last quarter: $1.20.
Sales
Next quarter’s sales estimate — $1.0B (from $1.0B to $1.0B). Last quarter: $996M.
Best top-analyst consensus in the sector · Healthcare
About BioMarin Pharmaceutical
- CEO: Alexander Hardy
- Employees: 3,221
- 770 Lindaro Street, San Rafael, CA, 94901, US
- www.biomarin.com
BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products. Among these are Vimizim, an enzyme replacement therapy targeting mucopolysaccharidosis (MPS) IV type A, a specific lysosomal storage disorder, and Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for individuals with MPS VI. Another notable offering is Kuvan, a unique synthetic oral version of 6R-BH4, prescribed for phenylketonuria (PKU), an inherited metabolic condition. Further expanding its product portfolio, BioMarin provides Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme administered via subcutaneous injection to lower blood Phe levels. Also available are Brineura, a recombinant human tripeptidyl peptidase 1 used in treating ceroid lipofuscinosis type 2, a variant of Batten disease; Voxzogo, a daily injectable c-type natriuretic peptide analog for achondroplasia; and Aldurazyme, a refined protein mirroring the naturally occurring human enzyme alpha-L-iduronidase. Beyond its established products, BioMarin has a robust development pipeline. This includes valoctocogene roxaparvovec, an adeno-associated virus vector undergoing Phase III clinical trials for severe hemophilia A. Additionally, BMN 307, an AAV5-mediated gene therapy, is in Phase 1/2 trials, aiming to normalize blood phenylalanine levels in PKU patients, while BMN 255 is also in Phase 1/2 trials for primary hyperoxaluria. Its clientele spans specialty pharmacies, hospitals, international government health bodies, and a network of distributors and pharmaceutical wholesalers. These services reach patients and healthcare providers across the United States, Europe, Latin America, and other global markets. BioMarin maintains strategic licensing and collaborative alliances with partners such as Sarepta Therapeuti
Data from the stock’s TipRanks forecast page, read 24 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗